# G LNK: HCP intelligence and compliant pharma engagement

Canonical: https://mudpie.ai/companies/g-lnk/
Breadcrumb: [Home](https://mudpie.ai/) / [Companies](https://mudpie.ai/companies/) / [G LNK: HCP intelligence and compliant pharma engagement](https://mudpie.ai/companies/g-lnk/)
Author: Ali Abouelatta (https://mudpie.ai/authors/ali-abouelatta/)
Published: 2026-09-19
Updated: 2026-09-19
Research type: Company profile
Method: Company and accelerator sources checked 2026-09-19. Product claims are attributed to their sources; this is research, not a hands-on product trial.

G LNK is a healthcare-intelligence and HCP-engagement platform for pharma and life-sciences teams. Its buyer is a commercial, medical-affairs or compliance team that needs to find the right clinicians, understand healthcare markets and document every engagement without stitching together databases, recruiters and spreadsheets.

## What it does

The [current G LNK site](https://www.glnkco.com/) describes searchable HCP profiles, hospital and health-system data, Open Payments and fair-market-value benchmarks, medical-device utilization, prescribing and claims data. It says the database covers 9.2M-plus clinician profiles, 68K-plus institutions, $11B-plus tracked payments, 200K-plus devices and billions of claims; these are company-published coverage figures.

The [YC launch](https://www.ycombinator.com/launches/Mx9-g-lnk-simplifying-collaboration-between-pharma-healthcare-professionals) describes a broader engagement workflow: identify a doctor, calculate compensation, contact the professional, track transfers of value and maintain country-specific codes of conduct. The current site lists a Health Explorer Subscription with 1,500 search credits per month and a Team plan with 2,000 credits per member; both are custom billed annually. No public price is shown.

## Why I’d look closer

The advantage is joining discovery and compliance context. A commercial team can search by specialty, procedure, prescribing pattern or geography, while finance and compliance can inspect payments and fair-market-value assumptions. Founder context fits: Rayan Ghandour studied chemistry and economics and worked in pharma/life-sciences consulting at PwC; Raouf Abujaber brings multimodal ML research and a multidisciplinary science background.

The tradeoff is data provenance and responsibility. A larger HCP database is not automatically current, complete or permitted for every outreach use. Payment and fair-market-value recommendations also need jurisdiction-specific review, not a green badge from a model.

## What I’d ask

Which sources update each profile and how are conflicts corrected? Can a compliance officer see the evidence behind a match, compensation suggestion and outreach record? How are consent, opt-outs and regional rules handled? What are the permitted uses of claims, Open Payments and contact data? Can the team export a complete audit trail?

## My editorial take

Shortlist G LNK if pharma or healthcare commercial work is being slowed by fragmented HCP research and compliance review. Start with one therapeutic area and a controlled engagement workflow, then validate source freshness, permissions and fair-market-value logic with compliance. The platform’s value is traceable context, not a larger contact list alone.

## Quick facts

| Field | Sourced detail |
| --- | --- |
| Product | HCP intelligence, provider data, payments, FMV and engagement workflow |
| Buyer | Pharma, biotech, medical-affairs, commercial and compliance teams |
| Published plans | Custom annual plans with 1,500 or 2,000 monthly search credits named |
| Coverage claims | 9.2M+ HCP profiles, 68K+ institutions and $11B+ tracked payments |
| Main question | Can the team defend every HCP match, payment assumption and outreach action? |

## Sources checked

| Source | Checked |
| --- | --- |
| [YC company profile](https://www.ycombinator.com/companies/g-lnk) | 2026-09-19 |
| [G LNK homepage](https://www.glnkco.com/) | 2026-09-19 |
| [G LNK YC launch](https://www.ycombinator.com/launches/Mx9-g-lnk-simplifying-collaboration-between-pharma-healthcare-professionals) | 2026-09-19 |

## Cohort context

G LNK is listed in Winter 2025. In our 2026-09-18 directory snapshot, 104 of 165 listed companies in that cohort have YC’s primary industry label B2B (63.0%). This is a current-directory comparison, not an original intake count or a performance ranking. [Nine-cohort dataset](https://mudpie.ai/research/yc-cohorts-2026-09-19.json).

## Public website snapshot

Observed 2026-09-19T16:19:35.520Z in raw homepage HTML. This records visible metadata and advertised links, not agent execution or product quality.

| Signal | Homepage observation |
| --- | --- |
| Product description metadata | Observed |
| Canonical link | Observed |
| H1 or H2 heading | Observed |
| Typed structured data | Observed |
| Docs/developer link | Not observed in this response |
| Pricing link | Observed |
| llms.txt link | Not observed in this response |
| Markdown alternate | Not observed in this response |

[Public observations](https://mudpie.ai/research/yc-homepage-links-2026-09-19.json) · [Collection method](https://mudpie.ai/research/yc-homepage-methods/README.md). Missing links here do not establish that a capability or file is absent elsewhere.


## Author disclosure

I cofound Lazyweb and publish Mudpie. This is an owner-written publication, not an independent testing organization. Research notes distinguish observations, sourced reporting and editorial judgment.